sCD40L concentrations in blood components
. | sCD40L, ng/mL . | . | |
|---|---|---|---|
| Blood components . | Nonimplicated TRALI, U . | Implicated TRALI, U . | |
| FP from healthy donors | 0.01 ± 0.003 | N/A | |
| FFP | 1.3 ± 0.13* | N/A | |
| WB-Plts | 7.9 ± 1.1* | 14.0 ± 3.0*† | |
| A-Plts | 11.8 ± 0.82* | 44.7 ± 4.5*† | |
. | sCD40L, ng/mL . | . | |
|---|---|---|---|
| Blood components . | Nonimplicated TRALI, U . | Implicated TRALI, U . | |
| FP from healthy donors | 0.01 ± 0.003 | N/A | |
| FFP | 1.3 ± 0.13* | N/A | |
| WB-Plts | 7.9 ± 1.1* | 14.0 ± 3.0*† | |
| A-Plts | 11.8 ± 0.82* | 44.7 ± 4.5*† | |
N/A indicates not applicable.
P < .05 from FP obtained through venipuncture from 5 healthy subjects.
P < .05 from WB-Plt concentrates that did not cause a transfusion reaction or from 5 A-Plt concentrates from healthy donors, respectively. Soluble CD40L concentrations were measured in duplicate by commercial human sCD40 ELISA. Numbers of units tested in all categories were as follows: 5 U FP, 10 U FFP, 57 samples from WB-Plt concentrates that did not cause transfusion reactions, 62 samples from WB-Plt concentrates implicated in TRALI, 5 U A-Plts from healthy donors, and 29 samples from A-Plt concentrates implicated in TRALI.